Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

This Company is Entering the US$25B COVID-19 Vaccine Market With its Oral Drug Delivery System

Jocelyn Aspa Jocelyn Aspa, The Market Herald
1 Comment| June 24, 2021

{{labelSign}}  Favorites
{{errorMessage}}

The COVID-19 pandemic has dominated the news for well over a year now, but headlines are shifting gears towards how the virus will be contained thanks to life science companies focusing their efforts on vaccinations.

Reports estimate that the global COVID-19 vaccine market will be valued at roughly $25 billion by 2024 fueled by a surge in cases in tandem with regional governments and international organizations supporting vaccine developments.

Rapid Dose Therapeutics Corp. (CSE:DOSE, OTC Pink:RDTCF, Forum) is one such company looking to tap into this growing market through its oral delivery system.

Headquartered in Burlington, Ontario, the biotechnology company has entered into the next stage of its research collaboration with McMaster University into an orally delivered COVID-19 vaccine candidate.

The second stage will leverage the company’s QuickStrip™ technology as a result of the successful first stage of the project.

The QuickStrip™ technology is a quick, convenient, precise and discreet oral fast-dissolving drug delivery system. Last July, the company initially entered into this partnership with McMaster University for the purpose of COVID-19 vaccine research of the drug delivery system to test or administer vaccines orally as an alternative to needle injections.

Rapid Dose Therapeutics updates on collaboration with McMaster University

In a press release, the company said that the initial study was completed by McMaster University’s research team, led by Dr. Alex Adronov, PhD and polymer expert. The study’s findings indicated the QuickStrip technology is effective at delivering proteins through the buccal or sublingual route of administration and enticing an immune response. As a result, this indicates the QuickStrip delivery system has the potential to be an ideal candidate for oral vaccine delivery.

Additionally, the National Research Council of Canada provided an initial supply of the SARS-CoV-2 spike protein for the university’s research team to infuse it into the QuickStrip for the second stage of the project. This intends to deliver the spike protein through oral mucosae in animal models with the goal of stimulating an immune response.

“These preclinical results, combined with the data analyzed to date, support the promise of QuickStrip technology in the delivery of therapeutics, including vaccines to potentially protect against SARS-CoV-2,” Mark Larché, PhD, McMaster University and head immunologist on the project, said in a release.

The research team also found that the proteins combined with QuickStrip were stable at 40 degrees Celsius, which means it does not need to be refrigerated.

Dr. Adronov said that thanks to these results, and as the second stage of the investigation progresses, it is expected this research could lead to new technologies in terms of vaccine delivery in the future.

Mark Upsdell, CEO of Rapid Dose Therapeutics, said that as a result of the National Research Council of Canada’s initial supply of the SARS-CoV-2 spike protein, the company was able to accelerate its timeline into the second stage quicker for relevant research related to COVID-19 vaccines.

“The provision of spike protein is so important since the spike protein itself provides the defense against COVID-19, thus the expected successful delivery of the spike protein on our QuickStrip is a potential COVID-19 vaccine itself,” Upsdell said. “We expect to have preliminary results from this stage two development work within a few months, which will lead us to seek partners in the commercialization of research.”

The benefits of oral vaccines

Traditional vaccine injections, which are done into the muscle, present challenges that are seen through the current delivery of COVID-19 vaccines.

For example, the cold-chain storage and transportation requirements lead to hefty costs in terms of the procurement and delivery of vials and syringes.

There is also an environmental impact on global CO2 emissions from transporting vaccines, disposing of vials, syringes and PPE in addition to displacing patients and healthcare professions.

Oral vaccinations eliminate these issues with a strip being placed on the inside of the cheek or under the tongue. As a result, this helps reduce the challenges seen in traditional vaccinations.

What’s more, oral vaccinations can be self-administered and sent through mail or courier and don’t require cold-chain storage. Oral vaccinations are also less invasive and can be delivered to remote populations.

Through Rapid Dose Therapeutics’ QuickStrip, an oral COVID-19 vaccination is closer to becoming a reality.

Investor takeaway

As the COVID-19 vaccine market accelerates, investors should be watching for companies stepping outside of the traditional box. Rapid Dose Therapeutics continues to make headway in advancing its oral COVID-19 vaccine candidate, and investors are paying attention.

Case in point, year-to-date the company’s share price has increased over 25 per cent. As Rapid Dose Therapeutics marches forward with the second stage of its program and beyond, investors can expect that the company will be a game-changer in this niche market.

FULL DISCLOSURE: This is a paid article produced by Stockhouse Publishing


{{labelSign}}  Favorites
{{errorMessage}}

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today